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Over time the association between cardiovascular diseases (CVD) and
osteoporosis has become more evident, especially as part of the aging
process. At first the association of osteoporosis with CVD was considered
as an artefact of aging, but it was revealed that after adjusting for age,
the association still persists [1, 2].
Although several former and recent studies have indicated the strong
association between CVD, atherosclerosis, antihypertensive drugs, statins
and bone density [3-7], hypertension seems to be an independent predictor
of low bone density [8]. In fact, the common pathophysiological pathway
of both diseases remains unknown, although different mechanisms and
pathways seem to have a critical role, including inflammation, oxidative
stress, lipid metabolism, and the sympathetic nervous system [9]. However,
the role of vitamin D is under debate [10].
Leukocyte (monocyte) and platelet activation induces inflammation by
stimulating cytokine production, including growth factors, chemokines,
and vasoactive molecules, as well as T cell migration [9]. According to this,
interleukin-6 (IL-6), IL-1, tumour necrosis factor-ʱ, macrophage colony
stimulating factor, receptor activator of nuclear factor ʺB (RANKL) and its
receptor, osteoprotegerin (OPG), osteopontin, C-reactive protein and
interferons orchestrate the atherosclerotic process which is common in
bone remodelling [9]. In addition, there are resorptive and remodelling
sites in atherosclerotic plaques similar to bone which have abundant
monocytes and preosteoclasts [9].
On the other hand, the critical role of platelets in wound healing,
haemostasis, fracture repair and atherosclerosis should be deeply
evaluated. According to our review, platelets and platelet-derived factors
can be viewed as new therapeutic targets for both diseases [11].
Other than the mentioned inflammatory mediators and cytokines,
several enzymes and metabolic pathways are linked to both senile
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diseases, of which cyclooxygenase (COX), and
homocysteine  can  be  indicated.  COX-derived
prostaglandins  contribute  to  various  cellular
biological functions and influence both diseases.
However, the net effect and the role of each of COX-
1 or COX-2 is not completely understood. In this
regard, and according to the different controversial
effects observed from nonsteroidal anti-inflam  -
matory drugs, the issue needs more investigations
[12]. In addition, the effect of n-3 fatty acids on bone
density as well as atherosclerosis originates from
its effect on COX enzyme is interesting. Our study
on postmenopausal women showed a negative
effect of n-3 fatty acids on a bone resorption marker
(pyridinoline) [13, 14]. 
Furthermore, there is a strong link between
hyperhomocysteinaemia, osteoporosis and CVD,
which needs to be investigated in detail [15]. The
link between cholesterol biosynthesis and bone
metabolism was proposed and confirmed in several
studies, and also it was revealed that statins affect
bone density, although the therapeutic pathway
which affects both is not obvious [7]. In addition to
the above-mentioned pathways, the role of the
sympathetic nervous system in bone metabolism
should be considered [16].
Supporting above-mentioned findings, a positive
correlation  was  found  between  bone  mineral
density and total body fat, and with abdominal fat
[17]. Also it has been shown that children with
juvenile rheumatoid arthritis have lower BMD and
higher serum OPG and RANKL [18].
Taken  together,  we  have  a long  way  into
surveying the strong link between osteoporosis and
CVD, and it is far more than finding one or two
biomarkers. In fact, both diseases should be viewed
as one complex senile disease which several risk
factors and pathogenesis affects it.
Furthermore, an interesting new issue in the
treatment of osteoporosis is the adverse effect of
calcium supplementation on the cardiovascular
system, which is a new, challenging issue and will
be discussed in detail in our next paper. 
References
1. Boukhris R, Becker KL. Calcification of the aorta and
osteoporosis. A roentgenographic study. JAMA 1972; 219:
1307-11.
2. Jie KG, Bots ML, Vermeer C, Witteman JC, Grobbee DE.
Vitamin K status and bone mass in women with and
without aortic atherosclerosis: a population-based study.
Calcify Tissue Int 1996; 59: 352-6.
3. Aronow WS. Osteoporosis, osteopenia and atherosclerosis
vascular disease. Arch Med Sci 2011; 7: 21-6.
4. Seo SK, Cho S, Kim HY, et al. Bone mineral density, arterial
stiffness,  and  coronary  atherosclerosis  in  healthy
postmenopausal women. Menopause 2009; 16: 937-43. 
5. Von der Recke P, Hansen MA, Hassager C. The association
between  low  bone  mass  at  the  menopause  and
cardiovascular mortality. Am J Med 1999; 106: 273-8.
6. Vogt MT, Cauley JA, Kuller LH, Nevitt MC. Bone mineral
density and blood flow to the lower extremities: the study
of osteoporotic fractures. J Bone Miner Res 1997; 12: 283-9.
7. Salari Sharif P, Abdollahi M. A systematic review on the
relationship between use of statins and osteoporosis. Int
J Pharmacol 2011; 7: 180-8.
8. Yazici S, Yaziki M, Korkmaz U, et al. Relationship between
blood  pressure  levels  and  bone  mineral  density  in
postmenopausal Turkish women. Arch Med Sci 2011; 7:
264-70.
9. Salari P, Abdollahi M. A comprehensive review of the
shared roles of inflammatory cytokines in osteoporosis
and cardiovascular diseases as two common old people
problems; actions toward development of new drugs. Int
J Pharmacol 2011; 7: 552-67.
10. Stojanovic O, Lazovic M, Lazovic M, Vuceljic M. Association
between atherosclerosis the role of vitamin D. Arch Med
Sci 2011; 7: 179-88.
11. Salari P, Abdollahi M. Controversial effects of non-steroidal
anti-inflammatory drugs on bone: a review. Inflamm
Allergy Drug Targets 2009; 8: 169-75.
12. Salari P, Rezaie A, Larijani B, Abdollahi M. A systematic
review of the impact of n-3 fatty acids in bone health and
osteoporosis. Med Sci Monit 2008; 14: RA37-44.
13. Salari  Sharif  P,  Asalforoush  M,  Ameri  F,  Larijani  B,
Abdollahi M.  The  effect  of  n-3  fatty  acids  on  bone
biomarkers  in  Iranian  postmenopausal  osteoporotic
women: a randomized clinical trial. Age 2010; 32: 179-86.
14. Salari  P,  Larijani  B,  Abdollahi M.  Association  of
hyperhomocysteinemia with osteoporosis: a systematic
review. Therapy 2008; 5: 215-22.
15. Salari Sharif P, Abdollahi M. The role of platelets in bone
remodeling. Inflamm Allergy Drug Target 2010; 9: 393-9.
16. Salari Sharif P, Abdollahi M. A systematic review on the
relationship between beta-blockers and bone health. Int
J Pharmacol 2010; 6: 577-83.
17. Salama HM, El-Dayem SA, Yousef H, Fawzy A, Abou-
Ismail L, El-lebedy D. The effects of L-thyroxin replacement
therapy on bone minerals and body composition in
hypothyroid children. Arch Med Sci 2010; 6: 407-13.
18. Kandil ME, Mourad A, Hamshary AE, Hussein G, Ah  med A,
Mawgoud SA. Evaluation of bone mineral density and
bone turnover markers in Egyptian children with juvenile
rheumatoid arthritis. Arch Med Sci 2009; 5: 434-42.